Results 61 to 70 of about 6,963,646 (317)

Radiobiological model-based approach to determine the potential of dose-escalated robust intensity-modulated proton radiotherapy in reducing gastrointestinal toxicity in the treatment of locally advanced unresectable pancreatic cancer of the head

Radiation Oncology, 2020
Background The purpose of this study was to determine the potential of escalated dose radiation (EDR) robust intensity-modulated proton radiotherapy (ro-IMPT) in reducing GI toxicity risk in locally advanced unresectable pancreatic cancer (LAUPC) of the ...
Vijay P. Raturi, Hidehiro Hojo, Kenji Hotta, Hiromi Baba, Ryo Takahashi, Toshiya Rachi, Naoki Nakamura, Sadamoto Zenda, Atsushi Motegi, Hidenobu Tachibana, Takaki Ariji, Kana Motegi, Masaki Nakamura, Masayuki Okumura, Yasuhiro Hirano, Tetsuo Akimoto   +15 more
doaj   +1 more source

High DCR and Better Survival in Patients with Advanced or Metastatic Gastric Cancer Receiving Anti-Angiogenic TKI plus Chemotherapy: A Real-World Study

Technology in Cancer Research & Treatment, 2023
Objectives: This study was carried out to assess the efficacy and drug toxicity of anti-angiogenic tyrosine kinase inhibitor (TKI) plus chemotherapy as second-line or above therapeutic regime in advanced or metastatic gastric cancer patients.
Caiyun Nie MD, Huifang Lv MD, Beibei Chen MD, Weifeng Xu MD, Jianzheng Wang MD, Saiqi Wang MD, Yingjun Liu MD, Yunduan He MD, Jing Zhao MD, Xiaobing Chen MD   +9 more
doaj   +1 more source

Social Functioning Within the First Years After Pediatric Brain Tumor Diagnosis and the Relationship With Family Psychosocial Risk

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Survivors of pediatric brain tumors (PBTs) can experience long‐term social difficulties, impacting quality of life. Beyond medical and environmental factors, family psychosocial risk may play a role in social outcomes by shaping the caregiving environment and may provide intervention options.
Renske H. Houben, Marisa H. Huisman, Martha A. Grootenhuis, Femke K. Aarsen, Marita Partanen   +4 more
wiley   +1 more source

Dose-to-medium vs. dose-to-water: Dosimetric evaluation of dose reporting modes in Acuros XB for prostate, lung and breast cancer [PDF]

, 2014
Purpose: Acuros XB (AXB) dose calculation algorithm is available for external beam photon dose calculations in Eclipse treatment planning system (TPS). The AXB can report the absorbed dose in two modes: dose-to-water (Dw) and dose-to-medium (Dm).
Pokharel, Shyam; Department of Radiation Oncology, 21st Century Oncology, Naples, Florida, USA, Rana, Suresh; Department of Medical Physics, ProCure Proton Therapy Center, Oklahoma City, Oklahoma, USA   +1 more
core   +1 more source

Macrophage Transcriptomic Alterations Driven by Alphavirus-Based Cancer Immunotherapy Vectors

Journal of Immunology Research
Cancer cells promote the polarisation of tumour-associated macrophages (TAMs) into pro-tumorigenic M2-like phenotype, contributing to cancer progression. Reprogramming TAMs by viral immunotherapy vectors represents a promising strategy for cancer therapy.
Ksenija Korotkaja, Darija Lapina, Zhanna Rudevica, Anna Zajakina   +3 more
doaj   +1 more source

Treatment outcomes of passive scattering proton beam therapy for stage I non-small cell lung cancer

Radiation Oncology, 2021
Introduction To investigate the treatment outcomes of passive scattering proton beam therapy using stereotactic ablative radiotherapy (SABR) or hypofractionated radiation therapy (RT) for inoperable patients or those who refused surgery for stage I non ...
Unurjargal Bayasgalan, Sung Ho Moon, Jong Hwi Jeong, Tae Hyun Kim, Kwan Ho Cho, Yang-Gun Suh   +5 more
doaj   +1 more source

Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal immunologic disorder marked by widespread lymphadenopathy and inflammation. Siltuximab, an interleukin‐6 (IL‐6) inhibitor, is the only FDA‐approved treatment for adult patients with iMCD.
Bridget Austin, Sheila K. Pierson, Kelley C. Dacus, Mateo Sarmiento Bustamante, Saishravan Shyamsundar, Larissa Borys, Kayla McHugh, Abiola Irvine, Yoojin Jo, Adam Bagg, Mary Jo Lechowicz, Daisy Alapat, Amy Chadburn, Megan S. Lim, Gordan Srkalovic, Frits van Rhee, David C. Fajgenbaum, Joshua D. Brandstadter   +17 more
wiley   +1 more source

Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study

Genome Medicine, 2021
Background Malignancies are molecularly complex and become more resistant with each line of therapy. We hypothesized that offering matched, individualized combination therapies to patients with treatment-naïve, advanced cancers would be feasible and ...
Jason K. Sicklick, Shumei Kato, Ryosuke Okamura, Hitendra Patel, Mina Nikanjam, Paul T. Fanta, Michael E. Hahn, Pradip De, Casey Williams, Jessica Guido, Benjamin M. Solomon, Rana R. McKay, Amy Krie, Sarah G. Boles, Jeffrey S. Ross, J. Jack Lee, Brian Leyland-Jones, Scott M. Lippman, Razelle Kurzrock   +18 more
doaj   +1 more source

The Impact of the COVID‐19 Pandemic on Childhood Cancer Survival: A Population‐Based Assessment of Survival Patterns Between 2015 and 2023 in Germany

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Numerous international studies have reported declines in new cancer diagnoses, delayed diagnoses and disruptions in cancer treatment following the implementation of COVID‐19 pandemic public health measures, raising concerns that these effects may ultimately contribute to increased cancer mortality.
Friederike Erdmann, Maike Wellbrock, Javier Louro, Arndt Borkhardt, Martin Schrappe, Claudia Trübenbach, Desiree Grabow, Cécile M. Ronckers, Joachim Schüz   +8 more
wiley   +1 more source

Immunotoxin therapy of cancer [PDF]

Nature Reviews Cancer, 2006
Rationally designed anticancer agents that target cell-surface antigens or receptors represent a promising approach for treating cancer patients. However, antibodies that bind these targets are often, by themselves, non-cytotoxic. By attaching potent toxins we can dramatically improve the clinical utility of some anti-tumour antibodies.
Pastan, Ira, Hassan, Raffit, FitzGerald, David J., Kreitman, Robert J.   +3 more
openaire   +2 more sources